Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (91 reviews)

For research use only.

Catalog No.S1091

91 publications

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )
FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )
Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )
J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnndJNrUUN3ME2wMlAzQDB4IN88US=>	M1XBV3NCVkeHUh?=
KS-1	NXOzXW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\FNWlEPTB;MD6wN\|g{PSEQvF2=	MU\TRW5ITVJ?
TE-11	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S4OmlEPTB;MD6wO\|gzOiEQvF2=	NEm2dZVUSU6JRWK=
EW-1	NIW1PVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\vdpVEUUN3ME2wMlA5PTh3IN88US=>	M1zCUXNCVkeHUh?=
HMV-II	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnTfG1KSzVyPUCuNFg5PDZizszN	NYDVdItDW0GQR1XS
COLO-205	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMUC0OVQh\|ryP	M3jKRnNCVkeHUh?=
ES1	M2[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjzOGhkUUN3ME2wMlExPjl4IN88US=>	NXLicZVSW0GQR1XS
GDM-1	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\iWXlSUUN3ME2wMlE{Pjd{IN88US=>	MoXEV2FPT0WU
ML-2	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPFTWM2OD1yLkG1PFk3KM7:TR?=	M4OxNnNCVkeHUh?=
Saos-2	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LCeWlEPTB;MD6xOlUzPiEQvF2=	MnvXV2FPT0WU
NCI-H1355	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMUixN\|Uh\|ryP	Moe1V2FPT0WU
G-401	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjCbm9KSzVyPUCuNVgzOyEQvF2=	NH6yT21USU6JRWK=
EW-16	NXrPdG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT6Umh1UUN3ME2wMlE5Pzd5IN88US=>	MWTTRW5ITVJ?
EW-7	NHfsW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW3ZlNjUUN3ME2wMlE5QDhzIN88US=>	NVjKZVFOW0GQR1XS
NCI-H727	NXLONldJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnFTWM2OD1yLkG5O\|k1KM7:TR?=	NWraNYVqW0GQR1XS
LCLC-97TM1	NEfodFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HzPWlEPTB;MD6yNFk2PSEQvF2=	MXXTRW5ITVJ?
NCI-H650	NVPMeol6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMkGzPFQh\|ryP	Mn\OV2FPT0WU
NCI-H2122	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfGTWM2OD1yLkKzNlk6KM7:TR?=	NXSyWWVrW0GQR1XS
SK-N-DZ	NHWyflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PtXWlEPTB;MD6yN\|Y6QCEQvF2=	MkSxV2FPT0WU
HT-29	NIrGfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlyzTWM2OD1yLkK0NlQ5KM7:TR?=	M3XORnNCVkeHUh?=
LB771-HNC	M1v6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLCVXZYUUN3ME2wMlI2QTF3IN88US=>	NFHUfppUSU6JRWK=
HT-144	M3zEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vBcGlEPTB;MD6yOlE6OSEQvF2=	NF7xNmpUSU6JRWK=
LAN-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf5NGRKSzVyPUCuNlY{PDhizszN	NGLORVRUSU6JRWK=
EW-18	M4DzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMkewNFEh\|ryP	MVrTRW5ITVJ?
LS-1034	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjLTWM2OD1yLkK3NVMzKM7:TR?=	NF75VpNUSU6JRWK=
EW-11	NFfweoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf5fYZwUUN3ME2wMlI5PDN{IN88US=>	MkjvV2FPT0WU
SNU-C1	NXz4T\|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fMOGlEPTB;MD6yPVMyOyEQvF2=	MYLTRW5ITVJ?
RS4-11	NHLr[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LkNWlEPTB;MD6zN\|c2QCEQvF2=	M4n2eHNCVkeHUh?=
ES4	M2T0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;VTWM2OD1yLkSxNFM5KM7:TR?=	M2PEenNCVkeHUh?=
COLO-320-HSR	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1r4OWlEPTB;MD60NVM3QCEQvF2=	MWjTRW5ITVJ?
NB10	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X1SGlEPTB;MD60OVQ{PyEQvF2=	NXjRUodGW0GQR1XS
BFTC-905	M1q3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;xUXk{UUN3ME2wMlQ3PzV6IN88US=>	MVLTRW5ITVJ?
A375	M1fnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HNOGlEPTB;MD60O\|YyPyEQvF2=	M3SzUnNCVkeHUh?=
SJRH30	NVjqXpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwNUC4NlIh\|ryP	NX\lZ5Q3W0GQR1XS
NOS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrhZYNSUUN3ME2wMlUzOjZ5IN88US=>	NHPz[ZZUSU6JRWK=
SIG-M5	M3fQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwNUO1OVch\|ryP	M{n5[nNCVkeHUh?=
DOK	M{TNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofLTWM2OD1yLkW1OkDPxE1?	NXTScmhTW0GQR1XS
NB69	NYrtbldoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe0b4ZVUUN3ME2wMlU5OjV5IN88US=>	MVLTRW5ITVJ?
SK-NEP-1	NUCxVWlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNkCyN\|Yh\|ryP	NYqyOZZNW0GQR1XS
SK-MM-2	M1nYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwNkW0PVEh\|ryP	M{PtbXNCVkeHUh?=
NCI-H358	NWLy[olkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP1UJk5UUN3ME2wMlY4ODh{IN88US=>	MVTTRW5ITVJ?
RH-1	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL4TWM2OD1yLke0PFU6KM7:TR?=	NXLpd25sW0GQR1XS
NH-12	NHOyU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnhTWM2OD1yLke2NFQ3KM7:TR?=	MlLvV2FPT0WU
TE-12	M3fFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwN{[0PFYh\|ryP	Mme1V2FPT0WU
COLO-668	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrJOnBZUUN3ME2wMlg1PjZ4IN88US=>	MVrTRW5ITVJ?
PANC-08-13	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPJTWM2OD1yLki2N\|c4KM7:TR?=	NEi1OlBUSU6JRWK=
HCC2998	M1m2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPn[JpPUUN3ME2wMlg5OjZ\|IN88US=>	NGrBOHVUSU6JRWK=
ABC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe2XHVKSzVyPUCuPVA{PTJizszN	M2TtTHNCVkeHUh?=
ES6	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTDfIdVUUN3ME2wMlkyODZ4IN88US=>	NWTySXJJW0GQR1XS
SNU-387	NGnJNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH74flhKSzVyPUCuPVk{QTNizszN	MU\TRW5ITVJ?
CMK	NVvoWWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XzdWlEPTB;MD65PVkzQSEQvF2=	MknEV2FPT0WU
SJSA-1	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTFwMEO2OVMh\|ryP	NHXn[nJUSU6JRWK=
SIMA	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHlXZdKSzVyPUGuNFY5OjVizszN	NHvrOndUSU6JRWK=
ES3	NFLhR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\DOGlEPTB;MT6xNlI6PyEQvF2=	M{D1SHNCVkeHUh?=
IGROV-1	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLUdWE1UUN3ME2xMlE2PDR2IN88US=>	NXfLTpVLW0GQR1XS
MEL-JUSO	NV;3ZZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\sTWM2OD1zLkG1O\|U6KM7:TR?=	MXnTRW5ITVJ?
T84	NF3YUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTFwMkC5NVQh\|ryP	M3m1UHNCVkeHUh?=
CAL-85-1	M{HV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LVSWlEPTB;MT6yN\|E{QCEQvF2=	Mni2V2FPT0WU
RD	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MomxTWM2OD1zLkK2OFU2KM7:TR?=	MUTTRW5ITVJ?
TE-8	NYf1[IFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv1TWM2OD1zLkOxOFYzKM7:TR?=	Mo\2V2FPT0WU
L-363	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7FTWM2OD1zLkO0NlA5KM7:TR?=	NW\aVXM4W0GQR1XS
EKVX	M{PSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmq0TWM2OD1zLkO0OVY5KM7:TR?=	NXLMNmVQW0GQR1XS
SK-MEL-3	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7WPWttUUN3ME2xMlQ5PTV4IN88US=>	MV7TRW5ITVJ?
TGBC24TKB	NETRU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlSwTWM2OD1zLkWwNVk{KM7:TR?=	MmW0V2FPT0WU
NCI-H1770	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwNUGxNVMh\|ryP	NXL4TXVjW0GQR1XS
HuH-7	M2C2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOwXWZKSzVyPUGuOlAxQThizszN	M2nUWXNCVkeHUh?=
HL-60	NXvvToE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3X5VmlEPTB;MT62OlkzQCEQvF2=	MW\TRW5ITVJ?
TE-1	NGfvbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTFwN{C5OFUh\|ryP	MYHTRW5ITVJ?
LC-2-ad	M2D2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwN{O4PFch\|ryP	NWrVfHVPW0GQR1XS
LB647-SCLC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nUWWlEPTB;MT63OlU5OyEQvF2=	NV\YU2FxW0GQR1XS
NCI-H2171	NGT4UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPNXpRKSzVyPUGuO\|c4OTZizszN	NWW2RWQxW0GQR1XS
SK-PN-DW	NWfKcY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljsTWM2OD1zLkmxNlk5KM7:TR?=	NEHqNpVUSU6JRWK=
MC-IXC	NXzyc21qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{mwXWlEPTB;MT65PFk5KM7:TR?=	NHP5VW5USU6JRWK=
LS-513	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm5WnI5UUN3ME2yMlA2OzB3IN88US=>	NXjaNWdYW0GQR1XS
EW-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fuOGlEPTB;Mj6wPVg1PCEQvF2=	MXHTRW5ITVJ?
OPM-2	NYrlR3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ywVGlEPTB;Mj6xNFIh\|ryP	NG\adJBUSU6JRWK=
LP-1	M1;UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[xVoJKSzVyPUKuNlU5ODdizszN	MnzZV2FPT0WU
LU-134-A	NGrEOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonXTWM2OD1{LkK3O{DPxE1?	NFzEVW5USU6JRWK=
CP66-MEL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:3S2lEPTB;Mj6yPVAyPCEQvF2=	MYnTRW5ITVJ?
HCC1143	NInROVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rTbWlEPTB;Mj60OVM3QCEQvF2=	M4jxcHNCVkeHUh?=
LOXIMVI	M3z4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXXTWM2OD1{Lk[wNlEh\|ryP	NIrvdo9USU6JRWK=
TE-10	NVeyWoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTJwN{C4N\|gh\|ryP	MUXTRW5ITVJ?
NCI-H1882	NIjsWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vP[mlEPTB;Mj63OVIzPyEQvF2=	NEDC[3NUSU6JRWK=
CHP-126	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorGTWM2OD1{Lke2N\|E4KM7:TR?=	MVTTRW5ITVJ?
NCI-H1623	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rwV2lEPTB;Mj65NlAzPCEQvF2=	M2\nZXNCVkeHUh?=
GB-1	M2[wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrqTWM2OD1{LkmzOFA1KM7:TR?=	MVHTRW5ITVJ?
RCC10RGB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TDfWlEPTB;Mj65OVI5OSEQvF2=	NEjSN45USU6JRWK=
NCI-H2141	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv1VZFKSzVyPUKuPVY5QTZizszN	M{\NOXNCVkeHUh?=
GI-ME-N	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELrfmFKSzVyPUOuNFA2PjVizszN	NUW2U\|R[W0GQR1XS
NCI-H526	NHrSO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfjSphKSzVyPUOuNFQxQDVizszN	MmH6V2FPT0WU
NCI-H747	NFfYcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vaS2lEPTB;Mz6wOFk6OiEQvF2=	Mo\xV2FPT0WU
SNU-423	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fEVGlEPTB;Mz6yNFMyOyEQvF2=	NYG4fW9FW0GQR1XS
A427	NV;pcW81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u1UmlEPTB;Mz6yOVY6QSEQvF2=	NH;vOGlUSU6JRWK=
CAL-12T	NU\Wc2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTNwNEC3NVMh\|ryP	M4nqdHNCVkeHUh?=
LU-99A	M4Sw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInwbG5KSzVyPUOuOFcyODVizszN	MVHTRW5ITVJ?
MS-1	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjMUFZKSzVyPUOuOVM1OjlizszN	MojsV2FPT0WU
SK-LU-1	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPuTWM2OD1\|Lke2Nlk2KM7:TR?=	NH3mVYZUSU6JRWK=
SW837	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTNwN{[zN\|Mh\|ryP	MoCxV2FPT0WU
ES8	NGnZWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\Lb45uUUN3ME2zMlg{QDd5IN88US=>	NHzOWIVUSU6JRWK=
MZ2-MEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPMfmtTUUN3ME2zMlkzODh4IN88US=>	M2X5VHNCVkeHUh?=
TGW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXzXJNRUUN3ME20MlAyOzFzIN88US=>	M2LZXHNCVkeHUh?=
GP5d	NVr3[XF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTRwMEWzOlIh\|ryP	M2TzbnNCVkeHUh?=
BB49-HNC	M3n2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzl[4ZKSzVyPUSuNVUzOTNizszN	MlHWV2FPT0WU
NB13	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH36N2NKSzVyPUSuNlY5QDdizszN	NEHhXHRUSU6JRWK=
NTERA-S-cl-D1	M3LxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;MTYxQUUN3ME20MlI5PjF3IN88US=>	NVHPSlQ5W0GQR1XS
NCI-H1648	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXmTWM2OD12LkK5PFE6KM7:TR?=	NGDuNZFUSU6JRWK=
LCLC-103H	NVy5d41KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHxVplQUUN3ME20MlMzOTl3IN88US=>	NVr2eYk5W0GQR1XS
LS-411N	NHHtTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;ZTWM2OD12LkS0PFg2KM7:TR?=	NEniRZRUSU6JRWK=
NCI-H1092	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnsTWM2OD12LkS1Olg4KM7:TR?=	M4rRXHNCVkeHUh?=
PANC-10-05	M{XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTRwNkm4OEDPxE1?	M4HrT3NCVkeHUh?=
DK-MG	M3;GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRwOEC5N\|Mh\|ryP	M3Lhe3NCVkeHUh?=
OVCAR-5	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;Hb4xKSzVyPUSuPFEzOjZizszN	NHjPToFUSU6JRWK=
CAL-39	M3Tie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnwTWM2OD12Lki3Olch\|ryP	NWrOTGh6W0GQR1XS
TE-441-T	M13NRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C1VWlEPTB;ND65NFU{PyEQvF2=	NXjZZY5GW0GQR1XS
MOLT-16	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT0[HpDUUN3ME20Mlk2OjV\|IN88US=>	Mnq1V2FPT0WU
MCF7	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\mbmlEPTB;NT6xOFUyPyEQvF2=	M3HJZ3NCVkeHUh?=
CAPAN-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTVwMkW3NFch\|ryP	Ml\uV2FPT0WU
PSN1	NHfrVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrqTWM2OD13LkK3NlM2KM7:TR?=	Mon0V2FPT0WU
NCI-H292	NVzUbJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTVwM{CwOFQh\|ryP	NHyyTZJUSU6JRWK=
CPC-N	Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2myRWlEPTB;NT6zPVQyQSEQvF2=	MX7TRW5ITVJ?
DoTc2-4510	M2LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTVwNEWzO\|Eh\|ryP	MnnSV2FPT0WU
LB1047-RCC	NUnXN5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTVwNUW5N\|Mh\|ryP	M1XkTnNCVkeHUh?=
MHH-ES-1	M2\6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rUXWlEPTB;NT61PVkxPyEQvF2=	NFjjSXlUSU6JRWK=
NMC-G1	M2H0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTVwN{CyNlch\|ryP	NU\K[\|l3W0GQR1XS
SW1710	NHTVOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTVwN{S3OVEh\|ryP	MYDTRW5ITVJ?
YAPC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTVwN{[yNFEh\|ryP	NX3HNWVYW0GQR1XS
22RV1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTVwOECwNVkh\|ryP	NIHNZ2RUSU6JRWK=
COLO-679	NFHpOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTVwOEi5OFgh\|ryP	MXHTRW5ITVJ?
TCCSUP	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfQfnhKSzVyPUWuPVMzPTlizszN	NGrh[YNUSU6JRWK=
C2BBe1	NWXXN4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXETWM2OD13LkmzPVch\|ryP	NGXBRnpUSU6JRWK=
TE-15	NWW3cmo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTZwME[2NFUh\|ryP	NGLCRZNUSU6JRWK=
SCLC-21H	NFvBSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPYbnpqUUN3ME22MlExQDR\|IN88US=>	NHTI[lhUSU6JRWK=
EoL-1-cell	NY\xUXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX1WXVQUUN3ME22MlE3PTZ\|IN88US=>	M{fOTHNCVkeHUh?=
NKM-1	NIT1ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETiXXZKSzVyPU[uNVY4OSEQvF2=	M1Lnc3NCVkeHUh?=
NCI-H1304	NFux[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTZwMke0Nlgh\|ryP	MYfTRW5ITVJ?
NB6	M3L1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7FUoFKSzVyPU[uNlk3OjJizszN	MkjMV2FPT0WU
NALM-6	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPhTWM2OD14LkOzNlMh\|ryP	Ml\0V2FPT0WU
NCI-H522	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rKZmlEPTB;Nj6zN\|MxPiEQvF2=	NYS4V5hUW0GQR1XS
MV-4-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTZwM{ewO\|kh\|ryP	MVfTRW5ITVJ?
LB2241-RCC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vuT2lEPTB;Nj6zPFY3PyEQvF2=	MkL4V2FPT0WU
NCI-H1417	NHTnNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv5TWM2OD14LkSwPFQ4KM7:TR?=	MVTTRW5ITVJ?
HT-1197	M4P4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTZwNUexNlIh\|ryP	M3\ZPHNCVkeHUh?=
P30-OHK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGq5WnRKSzVyPU[uOlI4PyEQvF2=	NFP0e3lUSU6JRWK=
ALL-PO	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHYPZc1UUN3ME22MlcyQTF4IN88US=>	NVLKVWxwW0GQR1XS
OVCAR-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXFV45KSzVyPU[uO\|U1ODVizszN	MW\TRW5ITVJ?
HCC2157	NX71ZWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rWdGlEPTB;Nj63O\|Q4PSEQvF2=	MYnTRW5ITVJ?
NCI-H838	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTZwOU[0PUDPxE1?	NEfkR4VUSU6JRWK=
NCI-H1299	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j5fmlEPTB;Nj65O\|A6KM7:TR?=	MoLRV2FPT0WU
SW954	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T6c2lEPTB;Nz6yNFA3QCEQvF2=	M1HuSnNCVkeHUh?=
NCI-H441	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnFVWhtUUN3ME23MlM1ODZ3IN88US=>	MWTTRW5ITVJ?
SK-MEL-2	NV\QSXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\MWVJKSzVyPUeuOFg{PzNizszN	MYnTRW5ITVJ?
KARPAS-45	NGjFWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\hTWM2OD15Lk[1PVI6KM7:TR?=	NXLl[5RJW0GQR1XS
CAL-54	NGPxRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPLNmxKSzVyPUeuPFI6PzdizszN	MojjV2FPT0WU
KYSE-180	NVexbW51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHoTWM2OD15Lki4PVQyKM7:TR?=	NWS3VJpyW0GQR1XS
NCI-H187	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzUR5hKSzVyPUeuPVU6PDdizszN	NX:yTJdGW0GQR1XS
RT-112	M3Xvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXBOYxKSzVyPUiuNFk3PzdizszN	MUfTRW5ITVJ?
NCI-H1437	M4nsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjrbXhKSzVyPUiuNFk4QTVizszN	M1LQfXNCVkeHUh?=
SNU-449	NHG5V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i0WWlEPTB;OD6yPFI4OiEQvF2=	MmHIV2FPT0WU
HCC1187	NX\JZllMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfsUFRKSzVyPUiuNlk{QTFizszN	NX[z[Ih4W0GQR1XS
NCI-H2030	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRThwM{e3NVQh\|ryP	NVrSUJREW0GQR1XS
HuO-3N1	NYq5Vm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRThwM{e4OFQh\|ryP	NULpc3dlW0GQR1XS
COLO-792	NFLWTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRThwNEG1Nlch\|ryP	MVnTRW5ITVJ?
MIA-PaCa-2	NH\FTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFW1bWFKSzVyPUiuPFU2ODhizszN	NVP3THF2W0GQR1XS
SK-N-FI	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jKWGlEPTB;OT6wOFI2KM7:TR?=	MYjTRW5ITVJ?
MMAC-SF	NVruSpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj0Sng1UUN3ME25MlA6PzVzIN88US=>	M2PEPHNCVkeHUh?=
NCI-H28	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjBdFVKSzVyPUmuNVA1PjlizszN	NXXj[4lvW0GQR1XS
ETK-1	NWTYZZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPxVZRKSzVyPUmuNlk6PzRizszN	NVWyWG1TW0GQR1XS
NCI-H1993	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTlwNESyOlEh\|ryP	NUjTUmtUW0GQR1XS
no-11	NYfGTHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PKTGlEPTB;OT60O\|EzKM7:TR?=	M3XqcnNCVkeHUh?=
ChaGo-K-1	NXGwcVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHUTWM2OD17LkWxOVg{KM7:TR?=	NGLqXVRUSU6JRWK=
NCCIT	M2jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjDO2lpUUN3ME25MlU{OTZ7IN88US=>	NHHHTVdUSU6JRWK=
SAS	NYTJUphTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTFyLkK0PEDPxE1?	NXzlTFBZW0GQR1XS
A673	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\pNWlEPTB;MUCuN\|cxPCEQvF2=	M{X0WHNCVkeHUh?=
NCI-H1522	M2PsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzDOZNkUUN3ME2xNE4{PzB5IN88US=>	NVPTNFZiW0GQR1XS
NCI-H810	NEntOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr0Wll5UUN3ME2xNE4{QTB5IN88US=>	M1PTcHNCVkeHUh?=
IST-MES1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf1U4tKSzVyPUGwMlQ2PjRizszN	M2fH[3NCVkeHUh?=
GR-ST	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7Z[YtsUUN3ME2xNE42ODJ2IN88US=>	NIG0N49USU6JRWK=
SUP-T1	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLZXJhNUUN3ME2xNE44OzF5IN88US=>	NXzxUmFGW0GQR1XS
NB5	M4\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTFyLkmwNlIh\|ryP	M{nQO3NCVkeHUh?=
MZ1-PC	M2GzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTFyLkm1O\|Eh\|ryP	M2PTcHNCVkeHUh?=
SK-CO-1	NFG4WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi0XINwUUN3ME2xNE46QTNzIN88US=>	MVjTRW5ITVJ?
Capan-2	NVn6fnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTpOndKSzVyPUGxMlMyQThizszN	NYezfodrW0GQR1XS
697	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[0TWM2OD1zMT62O\|U4KM7:TR?=	NFnPd2lUSU6JRWK=
REH	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPVbpRKSzVyPUGxMlc1PTFizszN	NGPldJRUSU6JRWK=
GI-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37xfWlEPTB;MUGuPFYyPSEQvF2=	MmHtV2FPT0WU
BB65-RCC	NWS3OXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIn4Xm5KSzVyPUGyMlA6OTZizszN	Ml7sV2FPT0WU
NCI-H1651	NH3PbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHZUGVKSzVyPUGyMlI1PzhizszN	NEnYO3ZUSU6JRWK=
NCI-H1618	M1nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnnTWM2OD1zMj6zPVc3KM7:TR?=	NXTH[\|Q3W0GQR1XS
NCI-H2081	M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrWb\|VKSzVyPUGyMlYyPDFizszN	MXrTRW5ITVJ?
GCIY	NVXNR5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDRenRKSzVyPUGyMlczOTNizszN	M2j3OHNCVkeHUh?=
NY	NWHLR25oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vFdWlEPTB;MUOuNFY1OyEQvF2=	MmT0V2FPT0WU
PANC-03-27	NX;YNVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3xdGZ{UUN3ME2xN{4xQDB5IN88US=>	MmruV2FPT0WU
BHY	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu5TWM2OD1zMz6yNVIyKM7:TR?=	MV3TRW5ITVJ?
SK-OV-3	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rsfmlEPTB;MUOuN\|c3OyEQvF2=	MVvTRW5ITVJ?
5637	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrwS4g1UUN3ME2xN{44PzV7IN88US=>	MYfTRW5ITVJ?
LC-1F	NUfmeHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIe1fFZKSzVyPUG0MlA{PTZizszN	NX:3V2I6W0GQR1XS
SNB75	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHKTWM2OD1zND6wN\|g{KM7:TR?=	MYnTRW5ITVJ?
CHP-212	M{iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPRTWM2OD1zND6wOFY1KM7:TR?=	MlTjV2FPT0WU
HT-1376	NXm5S3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTYcGlOUUN3ME2xOE4yOTJ4IN88US=>	M4TQPXNCVkeHUh?=
MONO-MAC-6	NYHifJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfjTWM2OD1zND6xOVAzKM7:TR?=	Ml3aV2FPT0WU
CA46	M4XsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjWXJJKSzVyPUG0MlE5OjdizszN	MV3TRW5ITVJ?
SCC-15	NXPzS495T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPvS21KSzVyPUG0MlU2QDNizszN	NIfWWHlUSU6JRWK=
ATN-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr1dYZKSzVyPUG0MlY3OjdizszN	NGfRWI1USU6JRWK=
NCI-H2405	M2DSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;QVlg3UUN3ME2xOE45OTV5IN88US=>	MWjTRW5ITVJ?
NCI-H716	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPkUW1KSzVyPUG0Mlg1QTNizszN	NHq0XZpUSU6JRWK=
SW620	NEn3N29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3YV2JKSzVyPUG0MlkxOTRizszN	NV2yeI16W0GQR1XS
NCI-H226	NVi3fXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF2LkmwPFUh\|ryP	MkHtV2FPT0WU
SW962	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTF2Lkm0N\|Ih\|ryP	NVTqXlhsW0GQR1XS
KYSE-150	NHLPfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;vTWlEPTB;MUSuPVU2KM7:TR?=	MkLzV2FPT0WU
OCUB-M	NI\RW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LXe2lEPTB;MUSuPVg5OyEQvF2=	NIXBTWRUSU6JRWK=
ES7	M4TMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\1d2dKSzVyPUG1MlA6QDRizszN	NXXCSlJzW0GQR1XS
SW1463	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTF3LkSyNlMh\|ryP	NF7Wd45USU6JRWK=
CAKI-1	M2TGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP1TWM2OD1zNT61N\|Q3KM7:TR?=	MV;TRW5ITVJ?
MKN28	M4fWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXH1bIZNUUN3ME2xOU42PDd7IN88US=>	MX;TRW5ITVJ?
SW13	NILHcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LtfmlEPTB;MUWuOlE5KM7:TR?=	M4DmVHNCVkeHUh?=
A3-KAW	M17KSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{D4O2lEPTB;MUWuPVY6PyEQvF2=	M1LycHNCVkeHUh?=
LU-65	NUT2RZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK5eIhKSzVyPUG1Mlk4PjhizszN	MVzTRW5ITVJ?
Calu-1	NUfKXotsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vFcmlEPTB;MU[uNFM3QCEQvF2=	MlXjV2FPT0WU
ST486	M2HuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17hVGlEPTB;MU[uNFQ{OSEQvF2=	MXHTRW5ITVJ?
BB30-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmWyTWM2OD1zNj6xNlQ3KM7:TR?=	NHzLbGRUSU6JRWK=
EGI-1	NWPtN49NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlm4TWM2OD1zNj60OFYh\|ryP	NHHzV\|JUSU6JRWK=
SH-4	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HLZ2lEPTB;MU[uOFc{OSEQvF2=	Ml7KV2FPT0WU
MN-60	NInqXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\wVmlEPTB;MUeuNlI6PyEQvF2=	MW\TRW5ITVJ?
MPP-89	NUPWRnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\2dHF{UUN3ME2xO{4zPDV7IN88US=>	NXjEUVlzW0GQR1XS
A2780	NHLCPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnTTWM2OD1zNz60NVM6KM7:TR?=	Mlq5V2FPT0WU
Daoy	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF5LkS2PVUh\|ryP	M1nscXNCVkeHUh?=
NCI-H2126	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC3TWM2OD1zNz60O\|cyKM7:TR?=	MYnTRW5ITVJ?
NCI-H1563	M2fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvJTWM2OD1zNz60PVE4KM7:TR?=	MkfTV2FPT0WU
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF5Lk[2OFgh\|ryP	MYXTRW5ITVJ?
786-0	NIrhTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:1TWM2OD1zNz64N\|U{KM7:TR?=	MmXuV2FPT0WU
AM-38	NEHmVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M334N2lEPTB;MUeuPVMxPiEQvF2=	Mli5V2FPT0WU
COLO-824	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D2cGlEPTB;MUiuOFQ{PiEQvF2=	M1:0[3NCVkeHUh?=
SK-MEL-30	NIi5VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG2TIVKSzVyPUG4MlUxQDJizszN	NUHERlJyW0GQR1XS
CESS	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j1N2lEPTB;MUiuO\|YxQSEQvF2=	NGLUUo5USU6JRWK=
BL-70	NV\IOZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PJR2lEPTB;MUiuPFE2PiEQvF2=	M3zTNXNCVkeHUh?=
NCI-H2170	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;6cJpqUUN3ME2xPE46OTd7IN88US=>	M3jl[3NCVkeHUh?=
HT-3	NYHkdHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF6Lkm4N{DPxE1?	NVuzN41sW0GQR1XS
BOKU	NWXvOoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHITWM2OD1zOT6wN\|gyKM7:TR?=	NGPLNVlUSU6JRWK=
HPAF-II	NXfFeZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrtWHllUUN3ME2xPU4{ODF3IN88US=>	M1rsd3NCVkeHUh?=
KGN	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe5RZpKSzVyPUG5MlQ4PjVizszN	M3nQbXNCVkeHUh?=
MC-CAR	M3XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfMTWM2OD1zOT62N\|E{KM7:TR?=	MX3TRW5ITVJ?
BHT-101	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXhTWM2OD1zOT63O\|ch\|ryP	NXHiSZJCW0GQR1XS
SW1783	NYf2NIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF7Lke4NFYh\|ryP	NHyzNFVUSU6JRWK=
KP-N-YN	NUDjdZczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1njdmlEPTB;MkCuNFI3OiEQvF2=	NI\2cmtUSU6JRWK=
LU-165	NXq0R3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XhfmlEPTB;MkCuOVU4OSEQvF2=	MmXPV2FPT0WU
GOTO	M1j2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJyLk[0OVEh\|ryP	M{L3dXNCVkeHUh?=
EFM-19	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXsU4MyUUN3ME2yNU4xPzF4IN88US=>	MmLFV2FPT0WU
CTV-1	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTJzLkGwOVQh\|ryP	M4jqc3NCVkeHUh?=
HEL	NGXqbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJzLkSyNVYh\|ryP	MknjV2FPT0WU
SNU-C2B	M{fQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDkTWM2OD1{MT60NlYh\|ryP	NGPDUFFUSU6JRWK=
ECC4	M{OyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJzLkewO{DPxE1?	NUjITFlPW0GQR1XS
NEC8	M{S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJzLkizOlgh\|ryP	M3\sR3NCVkeHUh?=
KMOE-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLRTWM2OD1{MT64PVIyKM7:TR?=	NYXQc5JZW0GQR1XS
NCI-H524	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJ{LkC4NFgh\|ryP	NGP6VWFUSU6JRWK=
WSU-NHL	NEXjeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTmbnFKSzVyPUKyMlE2PzdizszN	M4jvfXNCVkeHUh?=
SF126	NUe2eJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ{LkK0Olkh\|ryP	MnLrV2FPT0WU
HOP-92	M1HFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDLPHA{UUN3ME2yNk4{OTZ5IN88US=>	M4W1OnNCVkeHUh?=
CTB-1	NY\5dXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3ubG9KSzVyPUKyMlQ3PzdizszN	M1;xZ3NCVkeHUh?=
KYSE-270	M3jZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIm1cnpKSzVyPUKyMlk{PTdizszN	NVrrWXJHW0GQR1XS
SK-MEL-24	NYn4b5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj3cGRKSzVyPUKzMlE5PyEQvF2=	NIjQT4VUSU6JRWK=
Calu-3	NYrxfWVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLuTWM2OD1{Mz6yNVI5KM7:TR?=	MUjTRW5ITVJ?
GAMG	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHEO\|dzUUN3ME2yN{4zOzZ5IN88US=>	Mo\VV2FPT0WU
SW1573	M4rnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJ\|Lke0NVUh\|ryP	NUjTcJhXW0GQR1XS
MHH-NB-11	NXjpdXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTJ2LkCxPVQh\|ryP	M2XxbnNCVkeHUh?=
TK10	NXTyUGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r1SmlEPTB;MkSuOVAyOyEQvF2=	M4Pae3NCVkeHUh?=
LB373-MEL-D	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTJ2Lk[wOlQh\|ryP	M3i0WHNCVkeHUh?=
KALS-1	NEnZS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj6WHU6UUN3ME2yOE44OzJ5IN88US=>	NHnDTldUSU6JRWK=
HUTU-80	NVnib25UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkThTWM2OD1{NT64NFMzKM7:TR?=	NInQWVFUSU6JRWK=
HuP-T3	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDXTWM2OD1{Nj6xOlc1KM7:TR?=	NV7JRlkzW0GQR1XS
OE19	M2fQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHoZ4VKSzVyPUK2MlIyPTNizszN	NIfoNWJUSU6JRWK=
J82	NFvzS\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFm3e\|hKSzVyPUK2MlI1PzFizszN	MVzTRW5ITVJ?
DU-4475	M2qwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPYR41KSzVyPUK2MlM5OTlizszN	M1PBbHNCVkeHUh?=
DMS-53	M2rOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7pUGVKSzVyPUK2MlUyOzhizszN	NWfrVWJvW0GQR1XS
COLO-741	M3TucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvVT25KSzVyPUK2Mlg{PDRizszN	MnOxV2FPT0WU
SW48	NFT0bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjHRZJ5UUN3ME2yOk45QDJizszN	NF7VWIFUSU6JRWK=
IGR-1	NUnOdYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fQc2lEPTB;Mk[uPVM{PCEQvF2=	NXPzSHNPW0GQR1XS
639-V	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrGbYdUUUN3ME2yO{4xOjR3IN88US=>	M13TTXNCVkeHUh?=
LK-2	M4TEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTJ5LkSxOFEh\|ryP	M4\2ZXNCVkeHUh?=
NCI-H2347	NHnsXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPIbYZKSzVyPUK3Mlk3QTlizszN	NE\WT\|RUSU6JRWK=
NCI-H2228	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTJ6LkC5NFUh\|ryP	M3jWe3NCVkeHUh?=
LS-123	NUX4S4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rIV2lEPTB;MkiuNVI3OiEQvF2=	NEfTTItUSU6JRWK=
U031	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDydJVEUUN3ME2yPE4zPTJizszN	M{LKOXNCVkeHUh?=
NCI-H1792	NYjFT\|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofRTWM2OD1{OD60O\|IyKM7:TR?=	NHi3NllUSU6JRWK=
NCI-H2087	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTJ6Lke1OVIh\|ryP	MVvTRW5ITVJ?
NCI-H2342	M3vycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJ7LkWyNFgh\|ryP	NVvxfINSW0GQR1XS
SW626	NH;NXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnmTnBKSzVyPUK5Mlc2PiEQvF2=	NXzEWodVW0GQR1XS
LB2518-MEL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG4TWM2OD1{OT64NVUh\|ryP	MUjTRW5ITVJ?
RXF393	NFfQ[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXwTWM2OD1\|MD6wPVUzKM7:TR?=	MWjTRW5ITVJ?
LC4-1	NUTkPVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nRZmlEPTB;M{CuN\|A6OiEQvF2=	NIf0NG5USU6JRWK=
NCI-H1694	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPIZmZKSzVyPUOwMlY3OjRizszN	NILhS\|JUSU6JRWK=
K5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPETWM2OD1\|MD65O\|AzKM7:TR?=	MWDTRW5ITVJ?
HDLM-2	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTNyLkm3NlUh\|ryP	NUfsNJVxW0GQR1XS
BCPAP	NIPkTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnX2TWM2OD1\|MT64N\|c6KM7:TR?=	MUHTRW5ITVJ?
BC-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;hTWM2OD1\|Mj6xOFA{KM7:TR?=	NUS0bY1vW0GQR1XS
LB996-RCC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\nTWM2OD1\|Mj6yN\|U5KM7:TR?=	M3TpT3NCVkeHUh?=
NCI-H2009	NGnD[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWxTWM2OD1\|Mj60PVgyKM7:TR?=	NE\nZYZUSU6JRWK=
HTC-C3	NEDHNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHBc5d3UUN3ME2zN{44PTF7IN88US=>	MYfTRW5ITVJ?
LAMA-84	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTTdnFLUUN3ME2zOE41PDB5IN88US=>	NHL3dYVUSU6JRWK=
CCRF-CEM	M2rqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPQRVd6UUN3ME2zOE42PzF3IN88US=>	MlPZV2FPT0WU
AN3-CA	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfKVllGUUN3ME2zOU4xPTZ6IN88US=>	MljyV2FPT0WU
NCI-H1734	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTyZYxKSzVyPUO1MlI2PjFizszN	M3HmUnNCVkeHUh?=
Ca-Ski	M4rjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTN3LkSxNFEh\|ryP	NHzJXndUSU6JRWK=
U-266	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO1XWRKSzVyPUO1MlYyOTRizszN	NYrNdYFnW0GQR1XS
SBC-5	NFPxOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTN3Lke3PFEh\|ryP	NGPmTFFUSU6JRWK=
GT3TKB	NEi1cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ztS2lEPTB;M{euNVE2KM7:TR?=	MoLtV2FPT0WU
MDA-MB-175-VII	NFLhc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLuTWM2OD1\|Nz6yNlQ5KM7:TR?=	Mnn0V2FPT0WU
PFSK-1	NGnjVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnGW\|I{UUN3ME2zO{4zPDN3IN88US=>	MWfTRW5ITVJ?
IMR-5	M{i1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfxfJhKSzVyPUO3MlI1QDdizszN	NIq5dopUSU6JRWK=
Daudi	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTN5LkO1PVch\|ryP	M1vqXXNCVkeHUh?=
A498	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX5TWM2OD1\|Nz63NlE5KM7:TR?=	M2LH[HNCVkeHUh?=
SCC-4	NUfmO4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVG4ZZhrUUN3ME2zO{44QDR\|IN88US=>	NWfSSHZDW0GQR1XS
COLO-680N	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\tR2lEPTB;M{iuNlg5PSEQvF2=	MWLTRW5ITVJ?
SK-MES-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vnRWlEPTB;M{iuN\|IyPSEQvF2=	NVHKTZVKW0GQR1XS
SR	NFvSfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4C0eWlEPTB;M{iuOVQ6PSEQvF2=	NVLzUGpNW0GQR1XS
LNCaP-Clone-FGC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DPd2lEPTB;M{iuOVY{PyEQvF2=	NFLTfppUSU6JRWK=
SK-HEP-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[zTWM2OD1\|OD63PFIzKM7:TR?=	M{i5OnNCVkeHUh?=
BPH-1	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XYXWlEPTB;M{iuPFMzQSEQvF2=	Mn\CV2FPT0WU
NCI-H1755	NXL2TlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTN7LkW4NVch\|ryP	NIPtXJZUSU6JRWK=
LXF-289	M3LUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr4OllRUUN3ME2zPU45ODh2IN88US=>	M{HQZ3NCVkeHUh?=
SW1088	NXvnd4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXWd\|lKSzVyPUSwMlIyODdizszN	NUmwe2NzW0GQR1XS
MOLT-4	M3;kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TTdmlEPTB;NECuNlkxOSEQvF2=	M{jYbHNCVkeHUh?=
AsPC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWSySG44UUN3ME20NE41PTh\|IN88US=>	NYHxZZVVW0GQR1XS
HOP-62	M3\0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonuTWM2OD12MD62OVY5KM7:TR?=	M4\j[nNCVkeHUh?=
A172	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M32x[mlEPTB;NECuPFUyOSEQvF2=	NVL1THhkW0GQR1XS
SN12C	NX7FS4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TFb2lEPTB;NECuPVM5PSEQvF2=	M3LOSnNCVkeHUh?=
MDA-MB-231	M1v0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfpUmJKSzVyPUSwMlk5QThizszN	Mn\RV2FPT0WU
RPMI-2650	M4T3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHWTWM2OD12MT6xOVk{KM7:TR?=	MYPTRW5ITVJ?
KYSE-140	NVywWW5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV65T45LUUN3ME20NU45OTJ\|IN88US=>	NUXsTWliW0GQR1XS
KINGS-1	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fsWmlEPTB;NEKuOFY6PyEQvF2=	M3XETnNCVkeHUh?=
HSC-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljvTWM2OD12Mj62OlYyKM7:TR?=	M3mwPHNCVkeHUh?=
PC-14	NEDLeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n2OGlEPTB;NEOuNVg5OiEQvF2=	M1rscnNCVkeHUh?=
COR-L105	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLNTWM2OD12Mz62OVAzKM7:TR?=	Mk\BV2FPT0WU
BE-13	NYfpSHEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTGeJQ3UUN3ME20OE4zOzdzIN88US=>	M2O4b3NCVkeHUh?=
NCI-H661	M{nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTR2LkK5OVgh\|ryP	MYLTRW5ITVJ?
IST-MEL1	NX3sNIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HofWlEPTB;NESuN\|U6QSEQvF2=	NV3Wb2hZW0GQR1XS
HCC1806	NX3aZ\|dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTR2LkW4O\|Mh\|ryP	NVjG[FF{W0GQR1XS
COLO-800	NUTm[VJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33z[WlEPTB;NESuPFQ2OyEQvF2=	NWPDZ5d6W0GQR1XS
IST-SL2	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P4UmlEPTB;NEWuNVI1PyEQvF2=	NYThSnJYW0GQR1XS
8305C	M1\KT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTrTWM2OD12NT6zNFkh\|ryP	MVjTRW5ITVJ?
UACC-62	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rLSWlEPTB;NE[uNlg4PSEQvF2=	MnLBV2FPT0WU
COR-L23	NIfrWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmyR3Y4UUN3ME20O{4yQTlizszN	NXjaSJlMW0GQR1XS
EFE-184	M4jMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\tTWM2OD12Nz6zPFgh\|ryP	M{fmPHNCVkeHUh?=
DMS-114	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTDTWM2OD12Nz60NVQ6KM7:TR?=	M4O5dHNCVkeHUh?=
KYSE-520	NHPpc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfBfndUUUN3ME20PE42OzF3IN88US=>	NXLYSXN{W0GQR1XS
SNG-M	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXqeWtKSzVyPUS5MlQ{PCEQvF2=	NI\hWFJUSU6JRWK=
A2058	NFvwR\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjRTlNUUUN3ME20PU41QDh3IN88US=>	MlvDV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)